Table 1.
Baseline Characteristics of Entire Cohort
| Overall n (%) / mean ± SD |
No warfarin n (%) / mean ± SD |
Warfarin n (%) / mean ± SD |
p | |
|---|---|---|---|---|
| n | 860 | 270 (31) | 590 (69) | |
| Age (years) | 45.8 ± 15.3 | 44.5 ± 14.0 | 46.3 ± 15.8 | 0.12 |
| Female gender | 653 (76) | 189 (70) | 464 (79) | 0.01 |
| Race | ||||
| -White | 711 (83) | 220 (82) | 491 (83) | <0.01 (Ex) |
| -African-American | 48 (6) | 8 (3) | 40 (7) | |
| -Hispanic | 63 (7) | 32 (12) | 31 (5) | |
| Etiology of PAH | ||||
| -Idiopathic | 425 (49) | 114 (42) | 311 (53) | <0.01 |
| -SCL associated | 100 (12) | 21 (8) | 79 (13) | |
| -Other CTD | 66 (8) | 12 (5) | 54 (9) | |
| -CHD associated | 177 (21) | 73 (27) | 104 (18) | |
| -PoPH | 43 (5) | 34 (13) | 9 (2) | |
| -Other | 49 (6) | 16 (6) | 33 (6) | |
| Time from PH diagnosis to enrollment (months)* | 30.2 ± 55.6 Median: 10.9 |
37.8 ± 68.7 Median: 12.1 |
27.1 ± 48.9 Median: 10.2 |
0.17 |
| Initiation of bosentan or sildenafil during follow-up | 60 (7) | 21 (8) | 39 (7) | 0.53 |
| 6-MWD (m) | 335 ± 85 | 326 ± 79 | 336 ± 87 | 0.81 |
| NYHA functional class | ||||
| -II | 128 (15) | 48 (18) | 80 (14) | 0.23 |
| -III | 654 (76) | 196 (73) | 458 (78) | |
| -IV | 78 (9) | 26 (10) | 52 (9) | |
| Baseline Hemodynamics | ||||
| -RA (mmHg) | 10.0 ± 5.8 | 9.5 ± 5.7 | 10.2 ± 5.8 | 0.09 |
| -mPAP (mmHg) | 59.3 ± 15.5 | 62.9 ± 17.9 | 57.9 ± 14.2 | <0.01 |
| -PAWP (mmHg) | 9.5 ± 3.6 | 9.1 ± 3.5 | 9.7 ± 3.6 | 0.06 |
| -CO (L/min) | 4.1 ± 1.6 | 4.3 ± 1.6 | 4.1 ± 1.5 | 0.33 |
| -PVR (Wood U) | 13.6 ± 6.6 | 13.9 ± 7.3 | 13.4 ± 6.4 | 0.68 |
Abbreviations: 6-MWD: six-minute walk distance, CHD: congenital heart disease, CO: cardiac output measured by thermodilution, CTD: connective tissue disease, Ex: Fisher exact test, mPAP: mean pulmonary artery pressure, NYHA: New York Heart Association, PAWP: pulmonary artery wedge pressure, PoPH: portopulmonary hypertension, PVR: pulmonary vascular resistance, RA: right atrium, SCL: scleroderma.
*
Data only available in 733 patients (215 patients for the group on no warfarin and 518 for the group on warfarin).